URI:
   DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: TYSABRI (natalizumab)
       *****************************************************
       #Post#: 3095--------------------------------------------------
       (Abst.) PML and the spectrum of JC virus-related disease
       By: agate Date: November 22, 2020, 3:44 pm
       ---------------------------------------------------------
       From PubMed (November 22, 2020)--"Progressive multifocal
       leucoencephalopathy and the spectrum of JC virus-related
       disease," an abstract of a study appearing in Nature and done by
       investigators at the National Institutes of Health:
  HTML https://pubmed.ncbi.nlm.nih.gov/33219338/
       Excerpt from the abstract:
       [quote][font=BlinkMacSystemFont]Antiretroviral therapies greatly
       reduce the risk of HIV-related PML, but many modern treatments
       for cancers, organ transplantation and chronic inflammatory
       disease cause immunosuppression that can be difficult to
       reverse. These treatments - most notably natalizumab for
       multiple sclerosis - have led to a surge of iatrogenic PML. The
       spectrum of presentations of JCV-related disease has evolved
       over time and may challenge current diagnostic criteria.
       Immunotherapeutic interventions, such as use of checkpoint
       inhibitors and adoptive T cell transfer, have shown promise but
       caution is needed in the management of immune reconstitution
       inflammatory syndrome, an exuberant immune response that can
       contribute to morbidity and
       death.[/font][font=BlinkMacSystemFont][/size]
       [/font][font=Verdana][/size][/font][/quote][font=Verdana][/font]
       [font=Verdana][/size][/font]
       [font=Verdana][/size][Emphasis added][/font]
       *****************************************************